Frequency of cytochrome P450 3A4 variant genotype in transplant population and lack of association with cyclosporin clearance

European Journal of Clinical Pharmacology

Volumn 56, Issue 5, 2000, Pages 395-398

  Rivory, L P ^b   Qin, H ^a   Clarke, S J ^a   Eris, J ^a   Duggin, G ^a   Ray, E ^a   Trent, R J ^a   Bishop, J F ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b NONE

Author keywords

Cyclosporin; Cytochrome P450 3A4; Transplant

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; CYCLOSPORIN A; CYTOCHROME P450 3A4; MYCOPHENOLIC ACID; PHENYTOIN; PREDNISONE; VERAPAMIL; CYP3A PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450; IMMUNOSUPPRESSIVE AGENT; MIXED FUNCTION OXIDASE;

ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; ADOLESCENT; ADULT; AGED; BIOAVAILABILITY; FEMALE; GENETICS; MALE; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; PATIENT SELECTION;

ADOLESCENT; ADULT; AGED; BIOLOGICAL AVAILABILITY; CYCLOSPORINE; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PATIENT SELECTION; POLYMORPHISM, GENETIC;

EID: 0033626281     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280000166     Document Type: Article

References (11)

1. Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients
2. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
3. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4
4. Association of CYP3A4 genotype with treatment-related leukemia
5. Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control
6. The role of human cytochrome P450 enzymes in the metabolism of anti-cancer agents: Implications for drug interactions
7. NONMEM population pharmacokinetic modeling of orally administered cyclosporine from routine drug monitoring data after heart transplantation
8. Pharmacokinetic drug interactions with cyclosporin (part II)
9. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: Ethnic distribution and implications for prostate cancer risk
10. Interindividual differences in hepatic expression of CYP3A4: Relationship to genetic polymorphism in the 5'-upstream regulatory region
11. Population distribution and effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4